Delivery of autologous bone marrow precursor cells into the spinal cord via lumbar puncture technique in patients with spinal cord injury: A preliminary safety study

Callera, Fernando; Nascimento, Rogério Xavier Do

doi:10.1016/j.exphem.2005.11.006

Cited by 91 publications

(57 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This and the easy access to BMSCs for autotransplantation explains their use in several human treatment studies using a mixture of BMSCs and hematopoietic (mononuclear) cells (Callera et al, 2006;Chernykh et al, 2007;Saito et al, 2008;Yoon et al, 2007). Unfortunately, these reports included small patient cohorts only, used uncharacterized mixtures of bone-marrow cells, and were mostly not controlled.…”

Section: Neural and Glial Restricted Precursors In Combinationmentioning

confidence: 99%

A Systematic Review of Cellular Transplantation Therapies for Spinal Cord Injury

Tetzlaff

Okon

Karimi-Abdolrezaee

et al. 2011

Journal of Neurotrauma

489

463

View full text Add to dashboard Cite

Cell transplantation therapies have become a major focus in pre-clinical research as a promising strategy for the treatment of spinal cord injury (SCI). In this article, we systematically review the available pre-clinical literature on the most commonly used cell types in order to assess the body of evidence that may support their translation to human SCI patients. These cell types include Schwann cells, olfactory ensheathing glial cells, embryonic and adult neural stem=progenitor cells, fate-restricted neural=glial precursor cells, and bone-marrow stromal cells. Studies were included for review only if they described the transplantation of the cell substrate into an in-vivo model of traumatic SCI, induced either bluntly or sharply. Using these inclusion criteria, 162 studies were identified and reviewed in detail, emphasizing their behavioral effects (although not limiting the scope of the discussion to behavioral effects alone). Significant differences between cells of the same ''type'' exist based on the species and age of donor, as well as culture conditions and mode of delivery. Many of these studies used cell transplantations in combination with other strategies. The systematic review makes it very apparent that cells derived from rodent sources have been the most extensively studied, while only 19 studies reported the transplantation of human cells, nine of which utilized bone-marrow stromal cells. Similarly, the vast majority of studies have been conducted in rodent models of injury, and few studies have investigated cell transplantation in larger mammals or primates. With respect to the timing of intervention, nearly all of the studies reviewed were conducted with transplantations occurring subacutely and acutely, while chronic treatments were rare and often failed to yield functional benefits.

show abstract

Section: Neural and Glial Restricted Precursors In Combinationmentioning

confidence: 99%

A Systematic Review of Cellular Transplantation Therapies for Spinal Cord Injury

Tetzlaff

Okon

Karimi-Abdolrezaee

et al. 2011

Journal of Neurotrauma

489

463

View full text Add to dashboard Cite

show abstract

“…A low (0.3 x 10 6 MSC/kg) and a high cell dose (0.6 x 10 6 MSC/kg) product was prepared and transferred to 1 cc syringes. When translated to a clinical setting, the above doses will be comparable to the infusion of 0.1 x 10 6 /kg to 2.5 x 10 6 MSC /kg, which is similar to the range of MSC utilized or proposed in clinical studies [21,[24][25][26].…”

Section: Cell Infusionmentioning

confidence: 95%

The Intrathecal Infusion of Mesenchymal Stem Cells into Healthy Rabbits is Safe and Devoid of Neurological or Clinical Complications

Jj¹,

Pereira²,

Bartholomew³

et al. 2011

J Stem Cell Res Ther

View full text Add to dashboard Cite

Background: Cellular, molecular and transplantation studies using mouse and rat models of neurological diseases have revealed that Mesenchymal Stem Cells (MSC) represent a reliable candidate for cellular therapies for neurological conditions, including Amyotrophic Lateral Sclerosis (ALS) and Spinal Cord Injury (SCI). However, evaluation of safety aspects associated with route and dose of cell infusion, pivotal issues in cell therapy, has not been tested in large animals.

show abstract

“…1 In several studies, cell transplantation through less invasive methods such as intravenous or lumbar puncture has been examined. 8,[12][13][14][15] It has been shown that transplanted cells with the lumbar puncture method can migrate through the cerebrospinal fluid to the injured site, 8,16 and the results of this method are superior to systemic transplantation of cells. 15 Previously, SCs and MSCs have been applied in some studies, but individually and through direct injection or lumbar puncture, for which the safety appliance was identified.…”

Section: Discussionmentioning

confidence: 99%

Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome

et al. 2015

View full text Add to dashboard Cite

Delivery of autologous bone marrow precursor cells into the spinal cord via lumbar puncture technique in patients with spinal cord injury: A preliminary safety study

Cited by 91 publications

References 4 publications

A Systematic Review of Cellular Transplantation Therapies for Spinal Cord Injury

A Systematic Review of Cellular Transplantation Therapies for Spinal Cord Injury

The Intrathecal Infusion of Mesenchymal Stem Cells into Healthy Rabbits is Safe and Devoid of Neurological or Clinical Complications

Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome

Contact Info

Product

Resources

About